Carfilzomib

被引：167

作者：

Kortuem, K. Martin ^{[1
]}

Stewart, A. Keith ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol Oncol, Scottsdale, AZ USA

来源：

BLOOD | 2013年 / 121卷 / 06期

关键词：

UNFOLDED PROTEIN RESPONSE; SINGLE-AGENT CARFILZOMIB; PROTEASOME INHIBITOR CARFILZOMIB; REFRACTORY MULTIPLE-MYELOMA; 20 S PROTEASOME; ENDOPLASMIC-RETICULUM; OPEN-LABEL; BORTEZOMIB RESISTANCE; SELECTIVE INHIBITORS; THERAPEUTIC TARGET;

D O I：

10.1182/blood-2012-10-459883

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This spotlight review focuses on the second-generation proteasome inhibitor carfilzomib, which was recently approved by the US Food and Drug Administration for treatment of relapsed and refractory multiple myeloma patients who have received at least 2 prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of the completion of the last therapy. This review focuses on clinical trial data leading to drug approval and provides advice for treating physicians who are now accessing this drug for patients. (Blood. 2013;121(6):893-897)

引用

收藏

页码：893 / 897

页数：5

相关论文

共 79 条

[31] NF-κB as a therapeutic target in multiple myeloma [J].

Hideshima, T ;

Chauhan, D ;

Richardson, P ;

Mitsiades, C ;

Mitsiades, N ;

Hayashi, T ;

Munshi, N ;

Dang, L ;

Castro, A ;

Palombella, V ;

Adams, J ;

Anderson, KC .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (19) :16639-16647

[32] LMP2-specific inhibitors: Chemical genetic tools for proteasome biology [J].

Ho, Yik Khuan ;

Bargagna-Mohan, Paola ;

Wehenkel, Marie ;

Mohan, Royce ;

Kim, Kyung-Bo .

CHEMISTRY & BIOLOGY, 2007, 14 (04) :419-430

[33] Regulation of monoubiquitinated PCNA by DUB autocleavage [J].

Huang, TT ;

Nijman, SMB ;

Mirchandani, KD ;

Galardy, PJ ;

Cohn, MA ;

Haas, W ;

Gygi, SP ;

Ploegh, HL ;

Bernards, R ;

D'Andrea, AD .

NATURE CELL BIOLOGY, 2006, 8 (04) :339-U13

[34] Regulation of DNA repair by ubiquitylation [J].

Huang, TT ;

D'Andrea, AD .

NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2006, 7 (05) :323-334

[35] A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma [J].

Jakubowiak, Andrzej J. ;

Dytfeld, Dominik ;

Griffith, Kent A. ;

Lebovic, Daniel ;

Vesole, David H. ;

Jagannath, Sundar ;

Al-Zoubi, Ammar ;

Anderson, Tara ;

Nordgren, Brian ;

Detweiler-Short, Kristen ;

Stockerl-Goldstein, Keith ;

Ahmed, Asra ;

Jobkar, Terri ;

Durecki, Diane E. ;

McDonnell, Kathryn ;

Mietzel, Melissa ;

Couriel, Daniel ;

Kaminski, Mark ;

Vij, Ravi .

BLOOD, 2012, 120 (09) :1801-1809

[36] Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls [J].

Kaufman, RJ .

GENES & DEVELOPMENT, 1999, 13 (10) :1211-1233

[37] How proteolysis drives the cell cycle [J].

King, RW ;

Deshaies, RJ ;

Peters, JM ;

Kirschner, MW .

SCIENCE, 1996, 274 (5293) :1652-1659

[38] Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate [J].

Kisselev, AF ;

Callard, A ;

Goldberg, AL .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (13) :8582-8590

[39] Antigen processing by the proteasome [J].

Kloetzel, PM .

NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2001, 2 (03) :179-187

[40]

Kolb B, 2012, ASCO M ABSTRACTS S, V30, P8009

← 1 2 3 4 5 6 7 8 →